Literature DB >> 10457745

A health-related quality of life measure for use in patients with onychomycosis: a validation study.

D P Lubeck1, D Gause, J R Schein, L E Prebil, L P Potter.   

Abstract

Onychomycosis is a common nail disorder associated with pain, discomfort and varying degrees of physical impairment and loss of dexterity. Psychological and social limitations result from reactions of others to visible impairment. The goal of this research is to validate a questionnaire to measure the impact of toenail onychomycosis on health-related quality of life (HRQoL). One hundred and fifty onychomycosis patients were enrolled in an observational study at eight sites in the US. Attending physicians reported information on clinical status at enrolment. Patients completed a questionnaire covering HRQoL that included general and disease-specific items measuring the impact of onychomycosis on activities and appearance, plus problems and symptoms associated with toenail infection. The subscales of the instrument showed high internal consistency reliability (range = 0.63-0.95). Construct validity reflected the close association of physical functioning scores with onychomycosis impairment. Test-Retest reliability was good to excellent for all scales (ICC = 0.52-0.89). Discriminant validity was evidenced by persons who are younger and female reporting worse disease-specific HRQoL. Responsiveness to clinical change was noted for all disease-specific scale scores for improved patients. This instrument has demonstrated reliability, validity and responsiveness for use in observational and clinical studies of toenail onychomycosis patients. Data indicate that onychomycosis patients report significant pain and discomfort reflecting the need for HRQoL measurement.

Entities:  

Mesh:

Year:  1999        PMID: 10457745     DOI: 10.1023/a:1026429012353

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  10 in total

1.  Quality of life issues for patients with fungal nail infections.

Authors:  L Drake
Journal:  AIDS Patient Care       Date:  1995-12

Review 2.  Skin manifestations in AIDS patients.

Authors:  R Staughton
Journal:  Br J Clin Pract Suppl       Date:  1990-09

Review 3.  Topical and surgical treatment of onychomycosis.

Authors:  P R Cohen; R K Scher
Journal:  J Am Acad Dermatol       Date:  1994-09       Impact factor: 11.527

4.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

5.  Onychomycosis. Baseline results of an observational study.

Authors:  J R Schein; D Gause; D M Stier; D P Lubeck; M M Bates; R Fisk
Journal:  J Am Podiatr Med Assoc       Date:  1997-11

6.  The impact of onychomycosis on quality of life.

Authors:  L R Whittam; R J Hay
Journal:  Clin Exp Dermatol       Date:  1997-03       Impact factor: 3.470

Review 7.  Onychomycosis.

Authors:  A F Hoffman; V R Driver
Journal:  Clin Podiatr Med Surg       Date:  1996-01       Impact factor: 1.231

8.  A U.S. epidemiologic survey of superficial fungal diseases.

Authors:  M E Kemna; B E Elewski
Journal:  J Am Acad Dermatol       Date:  1996-10       Impact factor: 11.527

Review 9.  Mycology of nail disorders.

Authors:  G Midgley; M K Moore; J C Cook; Q G Phan
Journal:  J Am Acad Dermatol       Date:  1994-09       Impact factor: 11.527

10.  Quality of life of persons with onychomycosis.

Authors:  D P Lubeck; D L Patrick; P McNulty; S K Fifer; J Birnbaum
Journal:  Qual Life Res       Date:  1993-10       Impact factor: 4.147

  10 in total
  8 in total

Review 1.  Update on therapy for superficial mycoses: review article part I.

Authors:  Maria Fernanda Reis Gavazzoni Dias; Maria Victória Pinto Quaresma-Santos; Fred Bernardes-Filho; Adriana Gutstein da Fonseca Amorim; Regina Casz Schechtman; David Rubem Azulay
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

2.  Cost of treatment for onychomycosis. Data from a 9-month observational study.

Authors:  D M Stier; C Henke; J Schein; J Doyle; W H Schonfeld; J Broering
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

Review 5.  Onychomycosis: health-related quality of life considerations.

Authors:  James W Shaw; Vijay N Joish; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

Review 7.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

8.  The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis.

Authors:  Lori P Potter; Susan D Mathias; Monika Raut; Farid Kianifard; Amir Tavakkol
Journal:  Health Qual Life Outcomes       Date:  2006-08-15       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.